Neurocrine Bioscience buy The Goldman Sachs Group, Inc.
Start price
25.01.24
/
50%
€128.55
Target price
25.01.25
€140.87
Performance (%)
-15.87%
Price
11:24
€108.15
Summary
This prediction is currently active. The prediction for Neurocrine Bioscience disappoints with a performance of -15.87%. This prediction currently runs until 25.01.25. The prediction end date can be changed by The_Goldman_Sachs_Gr at any time. The_Goldman_Sachs_Gr has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Neurocrine Bioscience | 0.366% | 0.366% |
iShares Core DAX® | -0.168% | 4.802% |
iShares Nasdaq 100 | 2.946% | 3.520% |
iShares Nikkei 225® | 1.319% | 6.746% |
iShares S&P 500 | 2.044% | 3.551% |
Comments by The_Goldman_Sachs_Gr for this prediction
In the thread Neurocrine Bioscience diskutieren
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $134.00 to $153.00. They now have a "buy" rating on the stock.
Ratings data for NBIX provided by MarketBeat